Natalie Grover on Muck Rack

Natalie Grover

Verified
London
As seen in: Reuters, MSN, MSN Australia, MSN Brasil, MSN Canada, MSN Ireland, MSN Singapore, MSN Venezuela, UOL, Business Insider, Daily Mail and
Energy correspondent @Reuters; formerly focused on drugs & moonlights occasionally as footie reporter |natalie.grover@tr.com |ex @Guardian |Devoted to @Arsenal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Natalie

Contact Natalie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma

|
By John Sharp, Subodh Bhatta, Jennifer Huang, Colin Thomas Verified, Omar Elghawy, Lindsey A. Fitzgerald, Daniel Reef, Timothy Voorhees, Supriya Gupta, Natalie Grover Verified, Stefan K. Barta, Mazyar Shadman, Narendranath Epperla, Andinet Teferra
| Nature Verified
Dear Editor, Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma, with approximately 14,000 new diagnoses annually in the United States. Although FL has historically been considered incurable, front-line therapy can induce durable remissions. Nevertheless, up to 50% of patients require multiple lines of treatment [1].
Open in Who Shared Issue with article?

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

|
By Yucai Wang, Melissa Larson, Steven Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar Verified, Ashlee Joseph, Taylor Brooks, Brian Hill, David Bond, Kami J. Maddocks, Alexey B. Danilov, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Natalie Grover Verified, Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey Harris, Javier Muñoz, Philip Young, Craig Portell, Patrick M Reagan, Christine Ryan, Reid W. Merryman, Arash Velayati, Drew Gerber, Preetesh Jain, Michael Wang, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony Stack, Marcus Messmer, Mayur Narkhede, Amitkumar Mehta, Nilanjan Ghosh, Rahul S Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob L. Anna, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon Cohen, Peter Martin, Christine Argao, Nazneen B. Khan, I. Brian Greenwell, Sabarish R. Ayyappan, Tamara K. Moyo, Alexander V. Stanisic
| Nature Verified
Abstract Addition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020.
Open in Who Shared Issue with article?

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study

|
By Pallawi Torka, Natalie Grover Verified, Timothy Voorhees, Reem Karmali
| Wiley Online Library Verified
1 Introduction The incidence of all subtypes of marginal zone lymphoma (MZL) increases sharply with age [1] with the median age at diagnosis ranging between 65 and 70 years for splenic (SMZL), nodal (NMZL), and extranodal MZL (EMZL) of the mucosa-associated lymphatic tissue (MALT) [2].
Open in Who Shared Issue with article?
See all 7,606 licensed articles (8,574 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified